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Abstract
Background: Chemokine receptor 4 (CXCR4) is a multifunctional G protein-coupled receptor that is activated by its
natural ligand, C-X-C motif chemokine 12 (CXCL12). As a likely member of the lipopolysaccharide (LPS)-sensing
complex, CXCR4 is involved in pro-inflammatory cytokine production and exhibits substantial chemo-attractive
activity for various inflammatory cells. Here, we aimed to characterize the effects of CXCR4 blockade in systemic
inflammation and to evaluate its impact on organ function. Furthermore, we investigated whether CXCR4 blockade
exerts deleterious effects, thereby substantiating previous studies showing a beneficial outcome after treatment
with CXCR4 agonists in endotoxemia.
Methods: The CXCR4 antagonist AMD3100 was administered intraperitoneally to mice shortly after LPS treatment.
After 24 h, health status was determined and serum tumor necrosis factor alpha (TNF alpha), interferon gamma
(IFN gamma), and nitric oxide (NO) levels were measured. We further assessed oxidative stress in the brain, kidney,
and liver as well as liver biotransformation capacity. Finally, we utilized immunohistochemistry and immunoblotting
in liver and spleen tissue to determine cluster of differentiation 3 (CD3), CD8, CD68, and TNF alpha expression
patterns, and to assess the presence of various markers for apoptosis and oxidative stress.
Results: Mice treated with AMD3100 displayed impaired health status and showed enhanced serum levels of TNF
alpha, IFN gamma and NO levels in endotoxemia. This compound also amplified LPS-induced oxidative stress in all
tissues investigated and decreased liver biotransformation capacity in co-treated animals. Co-treatment with
AMD3100 further inhibited expression of nuclear factor (erythroid-derived 2)-like 2 (Nrf-2), heme oxygenase-1 (HO-1)
, and various cytochrome P450 enzymes, whereas it enhanced expression of CD3, inducible nitric oxide synthase,
and TNF alpha, as well as the total number of neutrophils in liver tissue. Spleens from co-treated animals contained
large numbers of erythrocytes and neutrophils, but fewer CD3+ cells, and demonstrated increased apoptosis in the
white pulp.
Conclusions: AMD3100 administration in a mouse model of endotoxemia further impaired health status and liver
function and mediated pro-inflammatory, pro-oxidative, and pro-apoptotic effects. This suggests that interruption of
the CXCR4/CXCL12 axis is deleterious in acute inflammation and confirms previous findings showing beneficial
effects of CXCR4 agonists in endotoxemia, thereby more clearly elucidating the role of CXCR4 in inflammation.
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Background
Chemokine receptor 4 (CXCR4) is a multifunctional G
protein-coupled receptor, activated by its natural ligand
C-X-C motif chemokine 12 (CXCL12) as well as by
macrophage migration inhibitory factor (MIF) and
ubiquitin [1, 2]. Both CXCR4 and CXCL12 perform
important biological functions during embryonic devel-
opment and hematopoiesis and have pleiotropic roles in
the immune system and during tissue repair processes
[3]. The fundamental importance of CXCR4 has been
demonstrated by the fact that mice lacking this receptor
are unable to survive due to critical defects in leukocyte
generation and hematopoiesis, leading to embryonic and
neonatal fatalities, as well as defects in heart and brain
development [4]. CXCL12 also exhibits substantial
chemo-attractive activity for various cells, such as mono-
cytes and T cells, both of which play critical roles in
inflammatory processes [5, 6].
CXCR4 was previously found to be involved in the
production of pro-inflammatory cytokines, such as inter-
leukin 6 (IL-6), which is increased after CXCR4 activa-
tion in microglia, human oral cancer cells, and
fibroblasts [7–9]. The authors attributed this observation
to a substantial activation of phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K), nuclear factor ‘kappa-
light-chain-enhancer’ of activated B-cells (NF-kB), and
activator protein 1 (AP-1). Additionally, CXCR4 activa-
tion with CXCL12 increased TNF alpha mRNA and
protein levels in primary astrocytes in vitro [10].
Despite these observations, the role of the CXCR4/
CXCL12 axis in inflammatory diseases remains
controversial and is not well characterized. Several
authors have reported beneficial outcomes after treat-
ment with various CXCR4 antagonists in models of
rheumatoid arthritis, colitis, and lupus erythematodes
[11–13]. Because elevated levels of CXCL12 were
present in the affected tissue, blockade of CXCR4
resulted in a decreased infiltration with CXCR4+
cells, such as T cells and neutrophils, leading to a
mitigation of the inflammatory conditions. In con-
trast, previous investigations from our group and
others revealed a beneficial outcome after adminis-
tration of a CXCR4 agonist in the lipopolysaccha-
rides (LPS)-induced model of inflammation in vivo
[14–16].
As a well-established animal model for systemic
inflammation and septic shock, administration of LPS in
mice can be used to study the anti-inflammatory poten-
tial of various drugs. LPS binds the lipopolysaccharide
binding protein (LBP) and interacts with a receptor
complex formed by CD14 (cluster of differentiation 14),
MD-2 (myeloid differentiation protein-2), and toll-like
receptor 4 (TLR4), which then activates TLR4-mediated
signal transduction. This leads to increased NF-kB
activation and enhanced production of proteases, react-
ive oxygen species (ROS), and nitrogen species (NOS)
[17]. Pro-inflammatory cytokines are also produced,
leading to an increased oxidative burst and decreased
biotransformation capacity of the liver [18]. In regard to
the numerous medications sepsis patients are usually
treated with, the preservation of the biotransformation
capacity is of substantial importance.
CXCR4 has been shown to be a component of the
LPS-sensing complex, suggesting that treatment with
CXCR4 agonists or antagonists could modulate TLR4
signaling [19]. However, little is known regarding the
precise effects of CXCR4 blockade in endotoxemia.
Therefore, in this study, we further aimed to unravel
the systemic impact of such a blockade on LPS-
induced organ damage, by treating mice with a com-
bination of the CXCR4 antagonist AMD3100 and
LPS. We hypothesized that several effects might only
become visible by antagonizing the receptor, rather
than administering a CXCR4 agonist, enabling us to
understand the impact of CXCR4 in endotoxemia.
We focused mainly on the health status of treated
mice and specifically, whether a CXCR4 blockade
would worsen endotoxemia, as suggested previously
[14–16]. We further measured the effect of AMD3100
on production of pro-inflammatory cytokines, induc-
tion of oxidative stress in different tissues, and the
liver biotransformation capacity. We focused on the
liver and spleen as two crucial organs to determine
the in vivo significance of the CXCR4/CXCL12 axis.
Consequently, we intended to understand the impact
of CXCR4 in endotoxemia more precisely and to
explore its influence in inflammation from another
perspective.
Methods
Animals and experimental procedure
The study was conducted under the license of the Thur-
ingian Animal Protection Committee (approval number:
02–044/14). The principles of laboratory animal care
and the German Law on the Protection of Animals, as
well as the Directive 2010/63/EU were followed. Male adult
C57BL/6 N mice (12-weeks-old, body weight 25–30 g;
Charles River Laboratories, Sulzfeld, Germany) were used,
and the animals were housed in plastic cages under stan-
dardized conditions (light-dark cycle 12/12 h, temperature
22 ± 2 °C, humidity 50 ± 10 %, pellet diet Altromin 1316,
water ad libitum). A total of 30 mice were randomly divided
into four groups: control, LPS, AMD3100 (n = 7 each), and
AMD3100 plus LPS (n = 9). LPS (Escherichia coli 0111:B4,
Sigma Aldrich, Steinheim, Germany) was injected intraperi-
toneally (5 mg/kg body weight, dissolved in phosphate-
buffered saline [PBS]) and AMD3100 (5 mg/kg body
weight, Tocris Bioscience, Bristol, UK) was administered in
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PBS intraperitoneally 2 h after endotoxemia onset. The
most appropriate LPS dose, as well as the final time point,
were determined in pilot studies, and the AMD3100 dose
was selected based on previous publications [20, 21]. At
24 h post-LPS treatment, body temperatures were mea-
sured, and the condition of the animals was assessed using
the Clinical Severity Score (CSS), as described previously
[22]. Afterwards, the mice were sacrificed using isoflurane
anesthesia, and their brains, kidneys, livers, and spleens
were removed, weighed, and either fixed in 10 % buffered
formaldehyde or snap-frozen in liquid nitrogen for
biochemical analysis or immunoblotting, respectively. Add-
itionally, whole blood was collected, and blood sugar levels
were determined using a commercially available blood
glucose meter and respective test strips (BG star®, Sanofi-
Aventis, Frankfurt, Germany). Subsequently, serum was
obtained and used for enzyme-linked immunosorbent assay
(ELISA) and enzymatic activity measurements. For histo-
logical analysis, the formalin-fixed organ samples were
embedded in paraffin blocks and cut into 4-μm thin
sections (n = 7 for each treatment group).
IFN gamma, TNF alpha, aspartate aminotransferase
(ASAT), alanine aminotransferase (ALAT), nitric oxide
(NO), urea, and creatinine assays
To determine the serum levels of IFN gamma, TNF
alpha, ASAT, ALAT, and NO, a mouse IFN gamma
ELISA kit (Pierce Biotechnology, Rockford, IL, USA), a
mouse TNF-alpha Quantikine ELISA kit (R&D Systems,
MA, USA), the EnzyChrom™ Aspartate Transaminase
Assay Kit, the EnzyChrom™ Alanine Transaminase Assay
Kit (both BioAssay Systems, Hayward, CA, USA) and
the Nitrate/Nitrite Colorimetric Assay Kit (Cayman
Chemical Company, Michigan, USA), respectively, were
used according to the manufacturer instructions.
Creatinine was determined by means of the Jaffé reac-
tion. Briefly, in a strongly alkaline medium, picric acid is
added to the sample. Under these conditions, it reacts
with creatinine to form an orange-red complex, which
can be measured photometrically at 492 nm. Serum urea
was measured using the commercially available colori-
metric Urea Assay Kit (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany), which utilizes coupled enzyme
reactions involving urease and glutamate dehydrogenase,
resulting in a product that can be detected at 570 nm.
Oxidative status in the tissues
The tissue glutathione content in its reduced (GSH) and
oxidized (GSSG) forms was analyzed by homogenizing
the samples with 11 volumes of 0.2 M sodium phosphate
buffer (5 mM ethylenediaminetetraacetic acid [EDTA];
pH 8.0) and four volumes of 25 % metaphosphoric acid.
After centrifugation (12000 g, 4 °C, 30 min), GSH
content was measured in the supernatants using a
colorimetric assay, as previously described [23]. The
GSSG concentration was assessed fluorometrically [24].
To determine the tissue content of lipid peroxides (LPO)
as thiobarbituric acid-reactive substances (TBARS), liver
samples were homogenized with 19 volumes of ice-cold
saline and analyzed fluorometrically, as previously
described [25].
Biotransformation capacity
To obtain 9000 g supernatants for analysis, livers were ho-
mogenized with 0.1 M sodium phosphate buffer (pH 7.4)
(1:2 w/v) and subsequently centrifuged at 9000 g for
20 min at 4 °C. The 9000 g supernatants were used to
assess the activities of several cytochrome P450 (CYP) en-
zymes, and the protein content of these fractions was deter-
mined using a modified Biuret method [26]. For
determination of CYP enzyme activities, the following
model reactions were performed: ethoxycoumarin-O-
deethylation (ECOD; [27]), ethoxyresorufin-O-deethylation
(EROD; [28]), methoxyresorufin-O-demethylation (MROD;
[28]), p-nitrophenol-hydroxylation (PNPH; [29]), and
pentoxyresorufin-O-depentylation (PROD; [28]).
Histopathology and immunohistochemistry
Samples for histopathology and immunohistochemistry
were prepared by cutting 4-μm sections from the paraffin
blocks and floating these onto positively charged
slides. Immunostaining was performed by an indirect
peroxidase-labeling method, as described previously [30].
Briefly, sections were de-waxed, microwaved in 10 mM
citric acid (pH 6.0) for 16 min at 600 W, and incubated
with the respective primary antibodies (Table 1) at 4 °C
overnight. Detection of the primary antibody was per-
formed using either a biotinylated goat anti-rabbit, a horse
anti-mouse, or a rabbit anti-goat IgG, followed by incuba-
tion with peroxidase-conjugated avidin (Vector ABC
“Elite” kit, Vector, Burlingame, CA, USA). Binding of the
primary antibody was visualized using 3-amino-9-ethyl-
carbazole (AEC) in acetate buffer (BioGenex, San Ramon,
CA, USA). The sections were then rinsed, counterstained
with Mayer’s hematoxylin (Sigma Aldrich, Steinheim,
Germany), and mounted in Vectamount™ mounting
medium (Vector Laboratories, Burlingame, CA, USA).
Additionally, TUNEL (TdT-mediated dUTP-biotin nick
end labeling) staining was performed using the In Situ
Cell Death Detection Kit, POD (Roche Diagnostics,
Mannheim, Germany), according to the manufacturer
instructions. All immunohistochemical stainings were
evaluated by two independent investigators. To detect the
liver glycogen content, periodic-acid-Schiff staining (PAS;
periodic acid, Schiff ’s reagent: Sigma Aldrich, Steinheim,
Germany) was performed, using standard protocols [31].
Identification of the specific cell types was based on their
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microscopic features along with the relative location of
the cells in the respective tissues.
Immunoblotting
Frozen liver and spleen samples (n = 4 from all treatment
groups) were weighed and added (1:4) to detergent buffer
(50 mM Tris-HCl, pH = 7.4, 150 mM NaCl, 5 mM EDTA,
10 mM NaF, 10 mM disodium pyrophosphate, 1 % Nonidet
P-40, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl
sulfate [SDS]) in the presence of protease and phosphatase
inhibitors (Complete Mini and PhosSTOP; Roche Diagnos-
tics, Mannheim, Germany). The samples were then
sonicated for 10 s and gently inverted for 1 h at 4 °C before
centrifugation for 30 min at 14800 g at 4 °C. Next, samples
were diluted with SDS sample buffer (62.5 mM Tris-HCl,
pH = 7.6, 2 % SDS, 20 % glycerol, 100 mM dithiothreitol,
0.005 % bromophenol blue), heated to 95 °C for 10 min,
cooled to room temperature, and subsequently subjected to
10 % SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and blotted onto polyvinylidene fluoride (PVDF)
membranes. Liver blots were incubated with anti-CYP3A2,
anti-CYP2B1, anti-CYP2E1, or anti-heme oxygenase-1 anti-
bodies, whereas spleen blots were incubated with anti-
cleaved caspase-3, anti-Nrf-2, or anti-CD3 antibodies,
followed by incubation with peroxidase-conjugated anti-
rabbit or anti-mouse secondary antibodies (Santa Cruz Bio-
technology, Heidelberg, Germany; dilution 1:5000) and en-
hanced chemiluminescence detection (Thermo Scientific,
Rockford, USA). β-actin, used as a loading control, was de-
tected using a monoclonal mouse antibody (sc-47778, Santa
Cruz Biotechnology, Heidelberg, Germany). All experi-
ments were performed in quadruplicate.
Blood cell quantification in the peripheral blood and in
liver and spleen
At 24 h post-LPS treatment, blood was collected from
all mice and transferred to vials containing EDTA in
order to prevent clotting. The samples were then ana-
lyzed using a Sysmex pocH-100iV Diff hematology
analyzer. Additionally, iNOS-positive neutrophils in the
livers and in the spleens of all mice were counted in 10
independent visual fields each at a magnification of 630×
or 200×, respectively, using a light microscope.
Statistical analysis
All statistical analyses and figures were computed with
GraphPad Prism software, v. 6.0 (GraphPad Software, La
Jolla, CA, USA). In all cases, experiments were
performed with seven animals per experimental group,
except for the immunoblots, which were carried out in
duplicate, with four animals per experimental group.
Statistical significance was determined by using the one-
way analysis of variance (ANOVA) and the Tukey post-
hoc test, except for the CSS and the different blood cell
types, which were analyzed by the non-parametric
Kruskal-Wallis test, followed by the Mann-Whitney U
test. A p value <0.05 (*) was considered as statistically
significant; a p value <0.01 (**) and a p value <0.001 (***)
are further specified. Data are presented as mean ±
standard error of the mean (SEM), except for CSS and
for the quantification of the different blood cell types,
which are presented as medians, with interquartile
ranges.
Results
Mortality, health status, weight development, and body
temperatures
To assess the effect of CXCR4 blockade on LPS-
mediated injury, male adult C57BL/6 N mice were
treated intraperitoneally with LPS, AMD3100,
AMD3100 plus LPS, or PBS (control) (n = 7 for all groups
except AMD3100 plus LPS, where n = 9). We first
conducted preliminary investigations to confirm the ap-
propriate LPS dose and found that 5 mg/kg body weight
Table 1 Primary antibodies used for immunohistochemistry (IHC) and immunoblotting (IB)
Primary antibody Type, Catalogue number Manufacturer Dilution IHC/IB Host species
CD3 polyclonal, sc-20047 Santa Cruz Biotechnology 1:500/1:200 Mouse
CD8 polyclonal, sc-7188 Santa Cruz Biotechnology 1:200/- Rabbit
CD68/ED1 monoclonal, MCA341R AbDSerotec 1:50/- Mouse
cleaved caspase-3 monoclonal, 9661 Cell Signaling Technology 1:600/1:1000 Rabbit
CYP3A polyclonal Daiichi Pure Chemicals 1:5000/1:10000 Goat
CYP2B polyclonal Daiichi Pure Chemicals 1:5000/1:10000 Goat
CYP2E1 polyclonal Daiichi Pure Chemicals 1:5000/1:10000 Goat
heme oxygenase 1 polyclonal, SPA-895 Biomol GmbH 1:5000/1:10000 Rabbit
iNOS polyclonal, sc-651 Santa Cruz Biotechnology 1:500/- Rabbit
Nrf-2 polyclonal, sc-722 Santa Cruz Biotechnology -/1:500 Rabbit
TNF alpha monoclonal, sc-52746 Santa Cruz Biotechnology 1:500/- Mouse
VEGF monoclonal, sc-7269 Santa Cruz Biotechnology 1:500/- Mouse
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was suitable in terms of causing no mortality within 24 h.
However, in our LPS plus AMD3100 group, two out of
the nine mice died, and these animals were not used for
further analysis.
The remaining animals were evaluated 24 h after LPS
treatment, and we found that those receiving LPS
displayed an impaired health status as compared to
controls, which was even more severe after co-
administration of AMD3100 and LPS, as evidenced by
increased CSSs, in comparison to the control and LPS-
treated mice (Fig. 1a). Specifically, co-treated mice
showed less activity, moved notably slower and with
more difficulty, slept more often, and exhibited a ruffled
fur, as compared to the other groups of animals. Further,
these mice consumed less food and water than even the
mice treated with LPS alone, which, inter alia, led to a
weight loss (Fig. 1b). Treatment of the animals with LPS
alone or with AMD3100 alone led to reduced body tem-
peratures when compared with the control mice. In
accordance with the other data, an additive effect was
observed in animals receiving both AMD3100 and LPS
(Fig. 1c).
Blood count, blood glucose, serum TNF alpha, IFN
gamma, NO, creatinine, and urea levels
Administration of LPS led to a decreased hematocrit
and reduced the amount of platelets and white blood
cells, when compared to the control group. However,
the additional AMD3100-mediated CXCR4 blockade re-
duced all these parameters even further. In contrast, the
neutrophil count in the peripheral blood was enhanced
after endotoxin challenge, whereas animals co-treated
with AMD3100 and LPS contained slightly fewer circu-
lating cells in comparison to the LPS group. Addition-
ally, AMD3100 alone was able to cause neutrophilia,
when compared to the PBS treatment control (Fig. 2a-e).
To further determine the systemic effect of a CXCR4
blockade, we assessed the amount of glucose in whole
blood, as well as the levels pro-inflammatory cytokines
and NO in the serum. After 24 h, endotoxin treatment
induced hypoglycemia, whereas co-administration of
AMD3100 and LPS reduced blood glucose levels even
further (Fig. 1d). Moreover, administration of LPS trig-
gered an elevation of serum TNF alpha and IFN gamma
levels by about 250 and 30 %, respectively, as compared
to the control group. AMD3100 in conjunction with
LPS further increased the serum levels of both cytokines
in endotoxic mice by more than 35 and 12 %, respect-
ively (Fig. 1e and f). LPS challenge also induced higher
serum NO levels, indicating increased oxidative stress,
and CXCR4 blockade further amplified these effects,
thereby leading to the highest NO levels observed
(Fig. 1g). Finally, blocking CXCR4 in endotoxemia pro-
duced higher serum creatinine levels, as compared to
the control or to the LPS groups. In contrast, serum
urea levels were decreased after LPS and (even more dis-
tinctly) after AMD3100 plus LPS challenge (Additional
file 1 b, c). For all parameters investigated, other than
neutrophil count, no relevant influence of AMD3100
alone was detectable.
Oxidative stress in different tissues
Due to the increased serum NO levels in mice treated with
LPS and LPS plus AMD3100, we assessed the oxidative sta-
tus in different organs. Therefore, we quantified the lipid
peroxidation products (LPO), as well as the levels of
reduced (GSH) and oxidized glutathione (GSSG) in the
brains, kidneys, and livers of treated and control mice. We
found that 24 h after endotoxemia onset, increased oxida-
tive stress was detectable in all organs investigated. In the
brains, LPS induced an elevated production of LPO, while
co-administration of AMD3100 and LPS produced even
higher levels (Fig. 3a). In parallel, the GSH/GSSG ratio was
decreased due to a reduced amount of GSH (Fig. 3b). Inter-
estingly, AMD3100 treatment alone also increased LPO
production and produced an enlarged GSH/GSSG ratio.
The oxidative states in the kidneys and in the livers were
found to be very similar (Fig. 3c-f). These results demon-
strate that endotoxin induces ROS production, which is
indirectly measureable by the increased LPO content and
the impaired glutathione status, and critically, co-treatment
with AMD3100 worsens these effects even further. The
liver, in particular, was strongly affected, as this organ
showed approximately 35 % higher LPO values and 15 %
less total glutathione content in animals co-treated with
LPS and AMD3100, as compared to the LPS group.
Liver
To better understand the underlying cause(s) of oxida-
tive stress observed in the different organs investigated,
we used immunoblotting and immunohistochemistry.
Here, we focused on the anti-oxidative enzymes, HO-1
and Nrf-2. As shown in Fig. 3g, our immunoblots re-
vealed that HO-1 was induced after LPS challenge. In
contrast, AMD3100 treatment alone led to a decrease in
HO-1 expression, and after co-administration of
AMD3100 and LPS, a further reduction was observed.
These data were confirmed by our immunohistochemi-
cal analysis (Fig. 4a-e). Here, HO-1 expression could be
detected mainly in Kupffer and in some pit cells, an
effect that was clearly visible after LPS challenge. Again,
we see that AMD3100 alone caused a distinct decrease
in HO-1 expression in comparison to both LPS-treated
and control animals, and after co-administration of
AMD3100 and LPS, HO-1 expression was almost com-
pletely abolished. For Nrf-2, immunoblot analysis
revealed an up-regulation after LPS administration,
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whereas co-treatment with AMD3100 and endotoxin led
to a decreased Nrf-2 expression in the tissue (Fig. 3g).
To further determine how CXCR4 blockade could in-
fluence liver integrity, we measured the serum levels of
ALAT and ASAT, ALAT, however, representing a more
specific indicator of liver inflammation. In comparison
to the control, LPS challenge caused an increase in
ASAT values by about 20 %. However, AMD3100 alone
was also able to induce ASAT levels to a comparable ex-
tent, and an additive effect was observed after combined
treatment with AMD3100 and LPS (Fig. 4j). Similarly,
endotoxin treatment augmented the serum concentra-
tions of ALAT by about 100 % in comparison to the
control, and the additional CXCR4 blockade caused a
further increase in ALAT levels by about 20 % (Fig. 4k),
indicating severe hepatocellular damage.
In light of these results and in order to gain a more
detailed understanding of liver function in treated
animals, we first performed periodic acid-Schiff staining
as a measure for liver glycogen content (Fig. 4e-h). Ex-
posure to LPS produced a massive loss of glycogen in
the livers, although some glycogen reserves were still
detectable. However, the additional CXCR4 blockade
was able to remove all glycogen reserves from hepato-
cytes, and the livers from co-treated mice showed struc-
tural changes, which could be attributed to slight edema
and intense fat accumulation. When determining the
liver protein content as a reference for the CYP model
reactions, we additionally assessed the turbidity value of
each sample and used this as an approximation of the
liver fat content. In concordance with our histological
data, AMD3100 caused an additional fat accumulation
in endotoxin-treated mice (Fig. 4l). While the samples of
LPS treated mice were more turbid than the controls by
about 110 %, the additional CXCR4 blockade provoked
an additional 220 % increase. In parallel, a significant
loss in liver protein content was observed. Whereas LPS
provoked a decrease by about 9 %, co-treatment caused
a >15 % loss, when compared with the control mice
receiving PBS only (see Additional file 1 a).
Another crucial parameter for assessing liver function
is the biotransformation capacity. As expected from our
previous investigations on the effects of CTCE0214D in
endotoxemia, we found that LPS caused a distinct loss
in the activity of several CYP enzymes in the liver. Not-
ably, whereas endotoxin decreased the activities of
CYP1A, 2A, 2B, and 2C (ECOD) to approximately 70 %
of the control values, the co-treatment further reduced
all activities by about 25 % (Fig. 5a). Similar results were
obtained when measuring the activities of CYP1A
(EROD), CYP1A2 (MROD), CYP2B (PROD), and CYP1E
(PNPH) (exemplary depicted in Fig. 5b and c). In com-
parison to LPS alone, additional administration of the
CXCR4 antagonist further diminished CYP activities by
approximately 30, 40, 25, and 30 %, respectively, when
compared to the LPS group. Similar results were obtained
in the corresponding Western blot analyses. Here, our
data indicate that endotoxin treatment reduced expression
of CYP2B, CYP2E1, and CYP3A in liver tissue (Fig. 5d),
and the addition of AMD3100 led to a further decline in
CYP enzyme expression; CYP2B isoforms, in particular,
were strongly affected. These results were further con-
firmed by our immunohistochemical findings. As shown
in Fig. 5e, the CYP enzymes are predominantly expressed
around the central veins. However, 24 h after LPS chal-
lenge, CYP expression was notably decreased, and after
co-administration of AMD3100, a further decrease was
observed (Fig. 5f and g).
In order to further clarify the mechanisms underlying
these effects, we performed additional immunohisto-
chemical stainings. Specifically, in accordance with the
massive oxidative stress observed in the livers of mice
treated with AMD3100 plus LPS, iNOS stainings
revealed several iNOS-overexpressing neutrophil granu-
locytes that had apparently entered the tissue. This effect
distinctly exceeded that seen after treatment with LPS
alone (Fig. 2f and 5h, i). Similar results were observed in
the corresponding staining for vascular endothelial
growth factor (VEGF). While some VEGF-positive gran-
ulocytes were seen in the periportal regions of mice that
had received LPS alone (Fig. 6a), after co-treatment with
AMD3100 and endotoxin, a larger number of granulo-
cytes were observed infiltrating the liver tissue and
spreading throughout the liver lobules (Fig. 6b).
To approximate the amount of T cells in the tissue, we
used CD3 as a marker because of its presence at all
(See figure on previous page.)
Fig. 1 General condition and systemic parameters. C57BL/6 N mice were treated either with LPS (5 mg/kg body weight), AMD3100 (5 mg/kg
body weight), with both substances or with the solvent PBS (control). 24 h after LPS administration, the Clinical Severity Score (a), the body
weight (b) and the body temperature (c) were assessed and the mice were sacrificed. Blood glucose content was determined from whole blood
(d) and serum was obtained for TNF alpha, interferon (IFN) gamma and nitric oxide (NO) measurements (e-g). Data are given as mean ± standard
error of the mean (SEM) or as median with interquartile ranges (CSS), respectively; n = 7 for each group. Statistical significant differences between
the different treatment groups were determined by using the one-way analysis of variance (ANOVA) and the Tukey post hoc test, except for the
CSS, which was analyzed by the non-parametric Kruskal-Wallis test followed by the Mann-Whitney-U test. They are indicated as follows: *, p < 0.05;
**, p < 0.01; ***, p < 0.001 vs. control animals; +, p < 0.05; ++, p < 0.01; +++, p < 0.001 vs. LPS treatment
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stages of T-cell development (Fig. 6c-f). While some
CD3+ Kupffer and pit cells were scattered throughout
the liver lobules in all treatment groups, after LPS treat-
ment, additional CD3+ lymphocytes and granulocytes
were detectable in the periportal regions, some of which
had already entered the tissue (Fig. 6d). Again, in com-
parison to the LPS group, CXCR4 blockade with
AMD3100 further enhanced the amount of CD3+ cells
present throughout the liver lobules. Figure 6f shows
several CD3+ granulocytes and lymphocytes infiltrating
the liver after co-treatment with LPS and AMD3100.
We then aimed to determine the liver cell population
responsible for the production of the elevated TNF alpha
serum levels observed in endotoxemia, particularly after
co-treatment with AMD3100 and LPS. Therefore, we
performed TNF alpha stainings in the liver tissue from
all treatment groups (Fig. 6g-j). As clearly evident from
Fig. 6j, sinusoidal endothelial cells are the major source
of TNF alpha production. Besides some Kupffer and pit
cells, these endothelial cells very strongly express this
pro-inflammatory cytokine when the livers are co-
challenged with AMD3100 and LPS for 24 h. Though to
a much lesser extent, endotoxin itself was also able to
induce TNF alpha expression, whereas the livers of
control and AMD3100-treated animals exhibit only few
TNF alpha-positive cells.
Spleen
The spleen is crucial for removing damaged red blood
cells and bacteria from the bloodstream. Therefore, we
were interested in how this organ responds to LPS, as
well as to the AMD3100 plus LPS challenge. We found
that LPS causes splenomegaly, as the spleen weights
were significantly increased by about 40 % after 24 h of
treatment, in comparison to those from the control
group (Fig. 7a). Histological examination of the spleen
further revealed an increased number of erythrocytes in
the red pulp and a modest accumulation of neutrophils,
along with a mild edema in the white pulp after LPS
treatment. Critically, administration of the CXCR4
blockade with AMD3100 intensified all these effects,
and 24 h post-treatment, the spleen weights from these
animals were about 20 % higher than those from mice
treated with LPS alone.
We next sought to determine the distribution of CD3+
cells in the spleen, in order to determine how these
results compare to our data from the liver. We observed
a large number of T-lymphocytes surrounding the peri-
arteriolar lymphoid sheaths in the white pulp of spleens
from control animals, and from mice treated with
AMD3100 alone (Figs. 7c and e). In comparison, endo-
toxin challenge led to a massive efflux of CD3+ cells
from the white pulp (Fig. 7d). Again, this effect was
much more pronounced after CXCR4 blockade with
AMD3100, and here, nearly no CD3+ lymphocytes were
detectable in the spleen tissue (Fig. 7f ). In combination
with our findings from the liver, these results indicate
that under inflammatory conditions, CD3+ cells seem to
leave the spleen and to migrate to other organs, such as
the liver.
To further substantiate our immunohistochemical
data, we then performed additional immunoblotting
experiments. As shown in Fig. 7b, administration of LPS
caused a distinct reduction in CD3 expression in the
spleen tissue, as compared to the control and to the
AMD3100-only treatment. This effect was more pro-
nounced after additional CXCR4 blockade with
AMD3100. In parallel, we also examined the presence of
CD8+ and CD68+ cells in the spleen tissue by immuno-
histochemistry. Here, in comparison to the control and
to the AMD3100-only treatment, a clear increase in the
number of CD8+ and CD68+ cells could be seen in the
white pulp in spleens from LPS-challenged mice, and
again, after combined treatment with AMD3100 and
LPS, this effect was more pronounced.
Because apoptotic processes are of substantial import-
ance in endotoxemia, we subsequently determined the
amount, and the distribution of cells undergoing apop-
tosis using TUNEL staining (Figs. 8a-d, and i). We found
that 24 h post-treatment, endotoxin caused an elevated
apoptosis in the white pulp. In particular, tingible body
macrophages appeared to be the main locus of cell
death, and co-treatment with AMD3100 further exacer-
bated these effects. By assessing the expression of
cleaved caspase-3 with immunohistochemistry and
immunoblotting (Fig. 7b), we were able to confirm these
observations, as the CXCR4 blockade amplified the
appearance of this pro-apoptotic enzyme. Finally, when
(See figure on previous page.)
Fig. 2 Blood cell quantification in the peripheral blood and in the organs. C57BL/6 N mice were treated either with LPS (5 mg/kg body weight),
AMD3100 (5 mg/kg body weight), with both substances or with the solvent PBS (control). 24 h after LPS administration, the mice were sacrificed
and the blood as well as the livers and spleens were collected. 50 μl of each blood sample were analyzed by using the Sysmex pocH-100iV Diff
hematology analyzer for hematocrit, platelet, white blood cell, lymphocyte and neutrophil count (a-e). Liver (f) and spleen sections (g-h) of each
mouse were stained by means of immunohistochemistry for iNOS expression and iNOS positive neutrophils were counted in ten independent vis-
ual fields each at a magnification of 630× or 200×, respectively, using a microscope. Data are given as median with interquartile ranges; n = 7 for
each group. Statistical significant differences between the different treatment groups were determined by using the non-parametric Kruskal–Wallis
followed by the Mann-Whitney-U test and indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. control animals; +, p < 0.05; ++, p < 0.01; ++
+, p < 0.001 vs. LPS treatment
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Fig. 3 Oxidative stress in different organs. C57BL/6 N mice were treated either with LPS (5 mg/kg body weight), AMD3100 (5 mg/kg body
weight), with both substances or with the solvent PBS (control). 24 h after LPS administration, the mice were sacrificed and different organs were
collected for the analysis of the tissue content of lipid peroxidation products as determined by thiobarbituric acid reactive substances (TBARS)
(a, c, e). As additional parameters, the GSH/GSSG ratio in the brain and kidneys (b, d) and the total glutathione content in the liver (f) are
depicted. Data are given as mean ± standard error of the mean (SEM), n = 7 for each group. Statistical significant differences between the
different treatment groups were determined by using the one-way analysis of variance (ANOVA) and the Tukey post hoc test and are indicated as
follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. control animals; +, p < 0.05; ++, p < 0.01; +++, p < 0.001 vs. LPS treatment. In (g) representative
examples of n = 4 independent immunoblot analyses of Nrf-2 and HO-1 expression in the liver are shown
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determining iNOS expression, we detected several
neutrophil granulocytes in both the red and the white
pulp of co-treated mice (Figs. 2g-h and 8e-h, and j). Crit-
ically, although LPS alone enhanced the amount of
iNOS-positive granulocytes in the red pulp, in compari-
son to control treatment, the additional CXCR4 block-
ade with AMD3100 amplified this effect in the red pulp
and induced additional iNOS expression in the white
pulp. Treatment with AMD3100 alone had no effect on
iNOS expression in the spleen.
Discussion
In contrast to other studies, which focused mainly on
the general outcome of the animals and on the migra-
tion of several inflammatory cell populations in different
inflammation models, we were primarily interested in
the precise effects of CXCR4 blockade in endotoxemia.
In particular, we focused on the systemic impact, as well
as the influence on organ function. Furthermore, we
intended to confirm previous investigations, which
utilized different CXCR4 agonists [15, 16, 32], and in
particular, our preceding study, in which we found that
the CXCL12 analog CTCE-0214D exerted protective
effects. Also, we aimed to indirectly show that CTCE-
0214D signals through CXCR4 and to further unravel
whether an interruption of the CXCR4/CXCL12 axis
results in a deleterious outcome in endotoxemia.
Here, our findings demonstrate a devastating impact
of AMD3100 in endotoxemia. This is consistent with
our previous study, in which almost all parameters were
improved after administration of the CXCL12 analog
CTCE-0214D [14]. From these results, we concluded
Fig. 4 Heme oxygenase-1 expression, serum ASAT, ALAT levels, glycogen and total fat content in the livers. C57BL/6 N mice were treated either
with LPS (5 mg/kg body weight), AMD3100 (5 mg/kg body weight), with both substances or with the solvent PBS (control). 24 h after LPS
administration, the mice were sacrificed and blood and livers were collected for further biochemical and histological analysis. (a-i): Representative
photomicrographs from one of seven different tissue samples stained for HO-1 expression are shown (immunohistochemistry (red-brown color),
counterstaining with hematoxylin, original magnification: (a-d, f-i) 400×, (c) 630×). The photomicrograph in (e) shows a single Kupffer cell at a
higher magnification (630×). As an approximate measurement for the fat content, we determined the turbidity value in the 9000 g supernatants
of the livers (l). j and k depict the serum concentrations of ASAT and ALAT of all treatment groups. Data are given as mean ± standard error of
the mean (SEM); n = 7 for each group. Statistical significant differences between the different treatment groups were determined by using the
one-way analysis of variance (ANOVA) and the Tukey post hoc test and are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. control
animals; +, p < 0.05; ++, p < 0.01; +++, p < 0.001 vs. LPS treatment; #, p < 0.05; ##, p < 0.01; ###, p < 0.001 vs. AMD3100 administration
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that this analog exerts its effects through CXCR4, and
thus, CXCR4 exhibits a massive impact on systemic
inflammation. This is also in good agreement with other
investigations showing that CTCE-0214D and ubiquitin
increase survival and diminish pro-inflammatory cytokine
levels in vivo. Also, in line with our results, administration
of AMD3100 in combination with LPS was associated
with an increased mortality in zebrafish [33] and specific
CXCL12 inhibitors revealed to be deleterious during
sepsis induced by cecal ligation and puncture (CLP) [34].
CXCL12 and its receptor are mandatory for the migra-
tion of several cells, including monocytes, neutrophils,
and hematopoietic progenitor cells. Delano et al. showed
that mobilization of neutrophils to the sites of infection
is CXCR4/CXCL12-dependent and that an interruption
of the CXCR4/CXCL12 axis impaired bacterial clearance
[34]. In addition, Guan et al. demonstrated that the
CXCL12 analog, CTCE-0214D, recruits polymorpho-
nuclear leukocytes (PMN) to the site of infection and
enhances their phagocytic activity, thereby improving
bacterial clearance in CLP-induced sepsis [32].
AMD3100 was also shown to promote inflammatory cell
egress, simultaneously inhibiting their recruitment to
sites of injury [35]. In addition, AMD3100 appeared to
Fig. 5 Biotransformation capacity and iNOS expression in the livers. C57BL/6 N mice were treated either with LPS (5 mg/kg body weight),
AMD3100 (5 mg/kg body weight), with both substances or with the solvent PBS (control). 24 h thereafter, the mice were sacrificed and the livers
were collected for biochemical and histological analysis. Ethoxycoumarin-O-deethylation [ECOD] (a), methoxyresorufin-O-demethylation [MROD]
(b) and p-nitrophenol-hydroxylation [PNPH] (c) activities in 9000 g supernatants are shown exemplarily. Data are given as mean ± standard error
of the mean (SEM); n = 7 for each group. Statistical significant differences between the different treatment groups were determined by using the
one-way analysis of variance (ANOVA) and the Tukey post hoc test and are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. control
animals; +, p < 0.05; ++, p < 0.01; +++, p < 0.001 vs. LPS treatment. d: CYP2B and CYP2E1 expression in liver tissue as determined by immunoblotting.
Representative examples of n = 4 independent immunoblots are depicted. e and g: CYP 2B isoforms expression in liver tissue as determined by
immunohistochemistry (red-brown color, counterstaining with hematoxylin). Representative photomicrographs from one of seven different liver
tissue samples are shown (original magnification: 200×). h and i: iNOS expression in liver tissue as determined by immunohistochemistry
(red-brown color, counterstaining with hematoxylin). Representative photomicrographs from one of seven different liver tissue samples are shown
(magnification: 630×, arrowheads: iNOS expressing infiltrating neutrophil granulocytes)
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cause a preferential release of neutrophils from the
lungs, while inhibiting their return to the bone marrow
for elimination from the blood [36], indicating that
CXCR4 blockade can negatively influence physiological
defense mechanisms. These findings may serve as pos-
sible explanations for our observations, as we detected a
larger number of neutrophil granulocytes in the livers
and spleens of mice treated with AMD3100 plus LPS, in
comparison to LPS-only treated animals. This suggests
that neutrophils entered the tissues and their return to
the bone marrow was likely blocked by the interrupted
CXCR4/CXCL12 signaling. This hypothesis is also sup-
ported by the severe apoptosis observed in the white
pulp of the spleen, as the large (unnecessary and
nonfunctional) cell amount is probably answered by an
increased cell death.
Furthermore, we identified fewer CD3+ cells in the
spleens, but evidently more CD3+ cells in the livers of
AMD3100 plus LPS co-treated mice, as compared to the
LPS-only treated controls, suggesting that CXCR4 block-
ade “shifts” pro-inflammatory cells to the livers to
provoke an inflammatory condition. Investigations by
Tsuchiya et al. revealed CXCR4 conditional knock-out
mice to exhibit increased numbers of CD3+ cells in the
liver when inducing a chronic liver disease with CCl4
[37], whereas others were not able to detect such signs
of inflammation in the liver when blocking CXCR4 [35].
Besides, we detected a reduced number of lymphocytes
in the bloodstream after 24 h, suggesting severe disease
progression, which seems to be a critical challenge for
the immune system. An enhanced degree of apoptosis,
mainly in the thymus and spleen, as well as the intensi-
fied immigration of lymphocytes into the tissues, may
serve as possible explanations. This also applies to the
neutrophil count in the blood. As we observed more
neutrophils in the organs, we hypothesize that CXCR4
blockade promotes their migration from the blood-
stream. This is supported by the observation that LPS
and AMD3100 alone induce neutrophilia when
compared to the control mice. However, these results
warrant further investigations. Altogether, we assume
that migration plays a predominant role in the observed
Fig. 6 Immunohistochemical evaluation of VEGF, CD3 and TNF alpha expression. C57BL/6 N mice were treated either with LPS (5 mg/kg body
weight), AMD3100 (5 mg/kg body weight), with both substances or with the solvent PBS (control). 24 h thereafter, the mice were sacrificed and
the livers were collected for immunohistochemical analysis of VEGF, CD3 and TNF alpha expression (red-brown color, counterstaining with
hematoxylin). Representative photomicrographs from one of seven different tissue samples each are shown (original magnification: (a, b) 630×,
(c-f) 400×, (g-j) 630×)
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phenotypes, as more CD68+ and CD8+ cells were found
in the spleens of co-treated mice, suggesting macro-
phages and cytotoxic T cells to immigrate after
AMD3100 administration in endotoxemia.
It is important to note that the complexity of the
CXCR4/CXCL12 axis has previously been clearly dem-
onstrated. For example, a study found that both a three-
fold increase in neutrophils, known to be injurious, and
a two-fold increase in hematopoietic stem cells, known
to be protective, occurred simultaneously at 36 h post-
injury. Here, the authors hypothesized that the neutro-
philic predominance may have mitigated any potential
beneficial effects from the hematopoietic stem cells [35,
38]. These findings may help to explain the seemingly
contradictory results obtained in different studies, such
as a beneficial impact of a CXCR4 blockade in
autoimmune diseases and a deleterious influence in
ischemia and acute inflammation [14, 39].
In accordance with previous investigations, which
found that CXCR4 agonists reduce serum levels of pro-
inflammatory cytokines in endotoxemia [14–16], we
detected increased levels of serum TNF alpha and IFN
gamma after CXCR4 blockade. Also Bach et al. detected
increased TNF alpha levels in polytrauma after
AMD3100 and LPS challenge [40]; however, the exact
cause of these observations remains unknown. As previ-
ously stated, CXCR4 may influence TLR4 signaling and
consequently lead to increased inflammatory responses.
However, whether an activation or blockade is beneficial
remains unclear and seems to depend on the cell line,
the in vitro stimulus, and on the type of inflammation in
vivo [19, 41]. As in other experiments, we attempted to
Fig. 7 Spleen weights and CD3 and cleaved caspase-3 expression in the spleen. C57BL/6 N mice were treated either with LPS (5 mg/kg body
weight), AMD3100 (5 mg/kg body weight), with both substances or with the solvent PBS (control). 24 h thereafter, the mice were sacrificed and
the spleens were collected for further analysis. a: Spleen weights. Data are given as mean ± standard error of the mean (SEM); n = 7 for each
group. Statistical significant differences between the different treatment groups were determined by using the one-way analysis of variance
(ANOVA) and the Tukey post hoc test and are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001; +, p < 0.05; ++, p < 0.01; +++, p < 0.001 vs.
LPS. b: CD3 and cleaved caspase-3 expression in the spleen as determined by immunoblotting. Representative immunoblots of n = 4 independent
analyses are shown. c-f: cleaved caspase-3 expression in the spleen as determined by immunohistochemistry (red-brown color, counterstaining
with hematoxylin). Representative photomicrographs from one of seven different tissue samples each are shown (original magnification: 200×)
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elucidate if THP-1 monocytes and macrophages are af-
fected after challenge with LPS alone, or in combination
with AMD3100 or CXCL12. However, we were unable
to detect any impact on TNF alpha secretion (Additional
file 1 d, e). We therefore hypothesize that a direct role
for CXCR4 in TLR4 signaling is secondary, and that mi-
gration likely plays the predominant role. The infiltrating
neutrophils and T lymphocytes may have contributed to
the observed deleterious conditions, as they are able to
produce large amounts of pro-inflammatory cytokines.
However, we discovered that, besides the infiltrating
cells, endothelial cells in the liver are the major source
of TNF alpha production. Whether these cells are dir-
ectly activated by LPS, or are stimulated by a previous
activation, e.g., from Kupffer cells or neutrophils, war-
rants further investigation. Up until now, there have
been few studies focusing on endothelial cells as a
source of pro-inflammatory cytokine production. In one
case, it was found that HUVECs stimulated with IL-1
alpha produced a moderate amount of TNF alpha,
whereas LPS did not induce TNF alpha secretion [42].
This underscores the complexity of the CXCR4/CXCL12
axis in inflammatory diseases.
We further found that AMD3100 in combination with
endotoxin caused massive oxidative stress, particularly
in the brains, kidneys, and livers, which can lead to a
severe damage of several cell structures, including lipids
and membranes, proteins, and DNA [43]. As mentioned,
we detected several neutrophils in the livers of
co-treated mice that likely contributed to the increased
TNF alpha and IFN gamma production. Both cytokines
have been reported to generate ROS via mitochondria
and NADPH oxidase and are able to heavily upregulate
iNOS [44, 45]. We confirmed these observations in our
study, as we identified several neutrophils in the livers of
the co-treated mice expressing iNOS. Correspondingly,
we measured elevated serum NO levels that may have
contributed to the massive oxidative stress in all organs
investigated. Furthermore, NO is known to be involved
in hypotension, cardiodepression, and vascular
Fig. 8 TUNEL assay and iNOS expression in the spleens. C57BL/6 N mice were treated either with LPS (5 mg/kg body weight), AMD3100 (5 mg/
kg body weight), with both substances or with the solvent PBS (control). 24 h thereafter, the mice were sacrificed and the spleens were collected
for immunohistological analysis (red-brown color, counterstaining with hematoxylin). Representative photomicrographs from one of seven
different tissue samples stained by means of the TUNEL assay or for iNOS expression are shown (original magnification: (a-h) 200×, (i, j) 630×)
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hyporeactivity in septic shock [46]. Therefore, it may
have negatively influenced the general well-being of the
mice, as evidenced by their decreased health status.
Interestingly, immunoblot and immunohistochemistry
analysis further revealed reduced HO-1 levels after
AMD3100 challenge in endotoxemia. The protective
effects of HO-1 have been clearly demonstrated, as HO-
1-deficient mice were found to be more susceptible to
microbial sepsis [47]. HO-1 functions as an anti-
oxidative and anti-inflammatory enzyme, and several
authors have reported decreased TNF alpha and ROS
levels after its activation [48]. In endotoxemia, oxidative
stress plays a critical role, and attenuation of a central
enzyme, such as HO-1, is likely to have detrimental
effects. Here, our findings are in agreement with our pre-
vious study, which found that the CXCL12 analog CTCE-
0214D induced the HO-1 expression and activity in the
liver [14]. Furthermore, co-treatment with AMD3100 and
LPS further diminished the levels of Nrf-2 in the liver, sug-
gesting CXCR4 blockade to be pro-oxidative, as activation
of Nrf-2 results in the induction of many cytoprotective
proteins, such as NAD(P)H quinone oxidoreductase 1,
glutamate-cysteine ligase, and HO-1 [49].
As we further measured a decreased biotransformation
capacity in livers from mice treated with AMD3100 plus
LPS, as compared to the LPS-only group, their ability to
detoxify and eliminate LPS-induced secondary products,
such as reactive oxygen species, was even more
restricted. Consequently, the fewer CYP families are
active, the fewer proteins are protected from degrad-
ation. Furthermore, biotransformation capacity is of crit-
ical importance, as septic patients are frequently treated
with several drugs, such as antibiotics. Therefore, we
postulate that CXCR4 blockade could further impair a
patient’s overall outcome by enhancing the side effects
from multiple medications. Again, with AMD3100, we
detected results that are consistent with our previous
study, in which we showed that CTCE-0214D treatment
improved the biotransformation capacity and the oxida-
tive status in the liver in endotoxemia. Together, these
results suggest that modulation of CXCR4 is of critical
importance in this disease.
In addition to biotransformation capacity, treatment
with AMD3100 in conjunction with LPS induced liver
damage by causing fat accumulation and slight edema,
along with increased serum ALAT and ASAT levels.
These findings are in good agreement with a recent
study, in which AMD3100 was used in combination with
CCl4 [35]. Here, the mice showed a trend towards in-
creased liver necrosis at 36 h, while ALAT and ASAT
levels were slightly, but not significantly, enhanced.
From these results, the authors concluded that there
may be a trend towards increased hepatic inflammation
when administering AMD3100 in combination with
CCl4. Furthermore, the decreased liver glycogen content
and the reduced blood glucose levels indicate a massive
glucose consumption. Kupffer and endothelial cells are
the major producers of various prostaglandins, which
have been shown to trigger glycogenolysis in the liver
[50, 51]. In addition, TNF alpha decreased gluconeogen-
esis in hepatocytes isolated from 10-day-old rats [52],
suggesting an excessive activation of inflammatory cells
to be responsible for the alteration of the glucose
homeostasis.
In order to further determine the impact of CXCR4
blockade on the kidneys, we measured the concentrations
of urea and creatinine in the serum (Additional file 1 b, c).
We postulate that the reduced serum urea levels seen after
LPS treatment, and that become more pronounced after
co-treatment with AMD3100, are attributable to impaired
liver function, as the liver produces the majority of urea.
Only in cases where kidney function is limited to 30 % or
less, do serum urea levels increase, and thus, this param-
eter may serve as a measure for kidney damage. Conse-
quently, our data also suggest that liver function is more
severely affected than kidney function in endotoxemia.
However, after AMD3100 plus LPS administration, serum
creatinine was significantly enhanced, suggesting that kid-
ney function is slightly impaired, at least in this instance.
As reported, co-administration of AMD3100 and LPS
caused splenomegaly, mainly due to an increased num-
ber of erythrocytes and neutrophils in the red pulp and
a slight edema, as well as the occurrence of some neu-
trophils in the white pulp. Splenomegaly is a well-known
response to LPS challenge, in which nonfunctional
erythrocytes and white blood cells are degraded. Appar-
ently, CXCR4 blockade resulted in more cells in need of
elimination that subsequently entered the spleen tissue,
resulting in a more severe inflammation and an impaired
health status. Correspondingly, we observed massive
apoptosis in the white pulp after co-administration of
AMD3100 and LPS. Further, cleaved caspase-3 expres-
sion was strongly increased, confirming a role for apop-
tosis. These observations are in accordance with our
previous investigations, in which the CXCL12 analog
was able to mitigate apoptosis in the white pulp, once
again suggesting CXCR4 modulation is of critical im-
portance in endotoxemia.
Conclusions
In summary, in the present investigation, we demon-
strated that CXCR4 blockade with AMD3100 exerts
deleterious effects in multiple facets of endotoxemia.
Specifically, we found that AMD3100 treatment in
conjunction with LPS further worsened the health
status, augmented pro-inflammatory cytokine expres-
sion, increased oxidative stress, and induced apoptosis in
different organs, as compared to LPS alone. Further, this
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blockade mediated an additional decrease in liver
biotransformation capacity, as well as a reduction in
HO-1 expression. We also observed an increased
immigration of several inflammatory cell populations
into the tissues in mice co-treated with AMD3100 plus
LPS, which likely contributed to the devastating overall
outcome observed in these animals. The present results
are consistent with previous findings, in which different
CXCR4 agonists were found to exert beneficial effects in
endotoxemia in vivo. In addition, by detecting effects
with the CXCR4 antagonist, AMD3100, that are in dir-
ect contrast to those observed with the CXCL12 analog,
CTCE-0214D, in endotoxemia, we can hypothesize that
treatment with CTCE-0214D exerts its protective effects
mainly via CXCR4. Collectively, these data enhance our
understanding of the CXCR4/CXCL12 axis in inflamma-
tory diseases and help to clarify the rare, and sometimes
contradictory studies, in this field.
Additional file
Additional file 1: Protein content in the liver, serum creatinine and urea
levels and TNF alpha assay in THP-1 monocytes as well as macrophages.
C57BL/6 N mice were treated either with LPS (5 mg/kg body weight),
AMD3100 (5 mg/kg body weight), with both substances or with the solvent
PBS (control). 24 h thereafter, the mice were sacrificed and the livers were
collected for the determination of the protein content in the 9000 g
supernatants by using the Biuret method (A). Also, the blood was obtained
and serum creatinine as well as serum urea levels were measured (B, C).
Data are given as mean ± standard error of the mean (SEM); n = 7 for each
group. Statistical significant differences between the different treatment
groups were determined by using the one-way analysis of variance
(ANOVA) and the Tukey post hoc test and are indicated as follows: *,
p < 0.05; **, p < 0.01; ***, p < 0.001 vs. control animals; +, p < 0.05; ++, p < 0.01;
+++, p < 0.001 vs. LPS treatment. THP-1 cells were cultured in RPMI 1640
supplemented with 10 % fetal bovine serum and 100 nM penicillin/
streptomycin (all Capricorn Scientific, Ebsdorfergrund, Germany) and were
cultured at a density of about 1.0 × 106/ml at 5 % CO2 at 37 °C. To obtain
THP-1 macrophages, cells were differentiated with PMA (phorbol
12-myristate 13-acetate; Sigma-Aldrich, St. Louis, MO) at a concentration of
40 ng/ml for three days. For the experiments, the cells were pretreated with
AMD3100 or CXCL12, respectively, 30 min before LPS was added. After
additional 12 h, the media were collected and analyzed for TNF alpha
concentration by using a TNF alpha ELISA Kit (Thermo Fisher Scientific,
Massachusetts, USA) (D, E). Data are given as mean ± standard error of the
mean (SEM); n = 3 independent experiments. (PDF 169 kb)
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